Postapproval Trial On Carotid Stenting in Patients With High Risk Vs Standard Risk for Open Carotid Endarterectomy(REAL)

Post Approval Non-randomized Double-arm Prospective Open Label Follow-up Trial on Carotid Stenting Using MOMA Proximal Embolic Cerebral Protection Device in Patients With High Risk vs Standard Risk for Open Carotid Endarterectomy(REALTrial)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02750644

Acronym

REAL

Enrollment

125

Registered

2016-04-25

Start date

2005-01-31

Completion date

2016-04-30

Last updated

2016-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid Artery Diseases

Brief summary

Until the irruption of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), carotid stenting (CAS) has been mainly offered to those patients considered at high risk for open carotid endarterectomy (CEA) based on the available data from large randomized clinical trials. High risk has been defined as (1) patients with severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy). Several recent studies have called medical high-risk into question for CAS indication. The purpose of this study is to evaluate the safety and perioperative and long-term effectiveness in patients with significant carotid artery stenosis with high-risk criteria (for CEA) treated with carotid stenting and proximal protection device (MOMA®) compared to patients with standard-surgical-risk features.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Symptomatic patients who have a transient ischemic attack, amaurosis fugax, or minor nondisabling stroke in the distribution of the study artery within 180 days of inclusion and have been shown carotid artery stenosis ≥50% by angiography, ≥70% by ultrasound, or ≥70% by CT angiography or MR angiography if ultrasound is 50% to 69% * Asymptomatic patients who have carotid artery stenosis of ≥60% by angiography, ≥70% by ultrasound, or ≥80% by CT angiography or MR angiography if ultrasound is 50% to 69%

Exclusion criteria

* Patient is unable to respond to external questions and stimuli and to exert a pressure with the contralateral hand * Patient has an myocardial infarction within 72 hours prior to carotid stenting * Patient has a major residual neurological deficit (stroke scales: Barthel ≤ 60, NIH ≥ 15 or Rankin \>3) at pre-procedure neurological exam * Patient had a transient ischemic attack (TIA) or amaurosis fugax within 48 hours prior to index procedure * Patient had a stroke or retinal artery occlusion within 1 month prior to index procedure * Patient has severe chronic renal failure (creatinine \> 2.5mg/dL) * The target carotid artery is completely occluded * The common carotid artery ostium has stenosis that required treatment * The presence of ipsilateral intracranial stenosis that requires treatment * The inability to position a stiff 0.035 guidewire in the external carotid artery * Contralateral occlusion of internal carotid artery and vertebral arteries

Design outcomes

Primary

Measure	Time frame	Description
all major adverse events	through 30-day follow-up or thereafter up to 4 years	the composite rate of all major adverse events (MAE), including death, stroke, and Myocardial Infarction, through 30-day follow-up or thereafter up to 4 years

Outcome results